AstraZeneca on Saturday said it was acquiring Alexion Pharmaceuticals for $39 billion, marking a significant expansion into the treatment of rare diseases of the immune system.
The deal — a mix of cash and stock — values Alexion at $175 per share, a 45% premium to Friday’s closing stock price.
Image: KRISTOFFER TRIPPLAAR/SIPA/AP
{iframe}https://www.statnews.com/2020/12/12/astrazeneca-to-acquire-alexion-for-39-billion-adding-blockbuster-immune-medicines/?utm_source=STAT+Newsletters&utm_campaign=6e9c14e526-EMAIL_CAMPAIGN_2020_12_13_11_46&utm_medium=email&utm_term=0_8cab1d7961-6e9c14e526-149827193{/iframe}